MRK vs PFE
MRK: Global pharmaceutical and vaccine leader with oncology, infectious disease, and animal health franchises, anchored by blockbuster immunotherapy Keytruda. PFE: Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular, and infectious disease.
Side-by-side fundamentals
| Metric | MRK | PFE | Edge |
|---|---|---|---|
| Price as of 2026-07-09 close | $125.07 | $24.25 | |
| Market cap as of 2026-07-10 | $310.1B | $138.1B | |
| P/E as of 2026-07-10 | 34.71 | 18.44 | PFE lower |
| PEG as of 2026-07-10 | 4.34 | -3.38 | PFE lower |
| Net margin as of 2026-07-10 | +13.6% | +11.8% | MRK higher |
| Gross margin as of 2026-07-10 | +78.1% | +74.8% | MRK higher |
| Operating margin as of 2026-07-10 | +18.2% | +15.4% | MRK higher |
| ROE as of 2026-07-10 | +17.9% | +8.4% | MRK higher |
| ROA as of 2026-07-10 | +7.0% | +3.6% | MRK higher |
| Debt / equity as of 2026-07-10 | 1.07 | 0.72 | PFE lower |
| Revenue growth (YoY) as of 2026-07-10 | +2.9% | +1.4% | MRK higher |
| Revenue CAGR (3y) SEC XBRL | +3.1% | -14.8% | MRK higher |
| Dividend yield as of 2026-07-10 | +2.7% | +7.1% | PFE higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-07-10 | 0.21 | 0.29 | |
| 1-year return as of 2026-07-09 close | +49.4% | -5.1% | MRK higher |
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.